TETRAMAB
Dead / Abandoned — Abandoned — failure to respond (as of 05 May 2025)
What this means for you
This application is over — abandoned 07 Mar 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 98559594
- Mark type
- Stylized text
- Filed
- 20 May 2024
- Abandoned
- 07 Mar 2025
- Attorney of record
- Christopher D. Olszyk, Jr.
Goods and services
- Class 001 — Chemicals: Multitarget, multiepitope, multivalent centralized antibody molecule structure used to incorporate multiple target antigen binders into a single antibody, namely, multi-specific therapeutic antibodies for scientific and medical research
- Class 005 — Pharmaceuticals: Multitarget, multiepitope, multivalent centralized antibody molecule structure used to incorporate multiple target antigen binders into a single antibody, namely, multi-specific reagent antibodies for medical diagnosis purposes
- Class 016 — Paper goods and printed matter: Printed educational and informational publications related to cancer, immunological, inflammatory and neurological disorders, namely, pamphlets, newsletters, guides
- Class 042 — Scientific and technological services: Providing prescription drug research information relating to drugs for the diagnosis and treatment of cancer, immunological, inflammatory and neurological disorders
- Class 044 — Medical, beauty and agricultural services: Providing healthcare information regarding the treatment of cancer, immunological, inflammatory and neurological disorders; Providing healthcare information regarding drugs for the treatment of cancer, immunological, inflammatory and neurological disorders
Owner
- Aarvik Therapeutics, Inc., Hayward, CA, US
Prosecution history
- 05 May 2025 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 05 May 2025 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 06 Dec 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 06 Dec 2024 — NON-FINAL ACTION E-MAILED
- 06 Dec 2024 — NON-FINAL ACTION WRITTEN
- 04 Dec 2024 — ASSIGNED TO EXAMINER
- 22 Nov 2024 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 20 May 2024 — NEW APPLICATION ENTERED